Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NDA...Not sure bout that, why would Amarin put data in hands of fudsters?
I’m sure BP is wearing the same rose colored glasses as you, and would gladly pony up the numbers you’re throwing out cause who needs to consider RISK in their forecast model lol.
Hence the webcast. A bit irritating that data is embargo’d for 6 weeks just to get 10 minutes of talk time....
BB, I agree with your assessment, however I thought JT already stated he expects in excess of 1B in sales in 2019. Would expect that he will be questioned on that topic...
Stone some talk a lot, others listen. It is amazing how many posters have popped up recently that have been in the stock for the distance, and just now have something to say. I’m seeing the same on stocktwits. I haven’t posted much myself, mostly because I don’t claim to have expertise in this space. I have though counted against the script numbers for a few years now, and have learned so much from the Knowledge shared on this board by a few that know their shit lol. And because of that I have been able to share that with a few others that have invested in Amarin as well. It’s all good, many will reap the rewards of believing in this company and its drug, and the intestinal fortitude that got us here...
I learned hard lessons, one of them was buying on margin, very risky and can turn your life upside down...which is effectively what you are doing. However you are already ahead of the game, so sell enough shares to cover all or a large percentage of the loan and let the rest ride. No one ever went broke by taking a profit!
Reading lesson...raf, Dad always said don’t always believe what you read...so as for his words...guess I did not take him seriously without further investigation. I find it intriquing enough to look into, however I have my doubts as to whether mtnb has the wherewithal to move their drug in phase two forward, and how it may or may not infringe on Amarin’s patents. But as I said before, there will always be competition looking to leapfrog. On the plus side, we are getting extra positive publicity because of mtnb...as rising tides raises all boats....
Wonder what GSK lovaza people were saying about Amarin back in the day....
Lol raf, i didnt read it so much as a proclaimation but rather seeking opinions on what others thought about mtnb in comparison with amarin. Yo still trying to figure out why saturday nite webcast?
Its your opportunity to educate him without spite, he appears new and maybe he doesnt have the knowledge or experience we have gained vested in amarin all these years.
Been holding and accumulating since 2011. My advice is to consider what you think is a likely buyout price, because imho, the odds are in favor of that happening before any Gia path results in a pps of 150-500. Gia doesn’t happen overnite, and I would have to believe if Gia path is taken...think capital raise thru secondaries
Will be on the table.
Jomama, I believe you have arrived at a sound conclusion, some people are unable to have a discussion with others without an attacking or belittling style. Biotech is always evolving, and there will always be the challenge of a better drug...so it’s prudent as an investor not to be blinded, but to keep ones eyes open on the landscape.
When you say “most of you”, are you including mgnt and Bakker bros?
Im close to being a millionaire for the first time in my life...but i can honestly say 17% wouldnt have got me there Py. But hey what do i know...??
Well written unlike some of the other crass comments. I always thought kiwi was a bit too negative but did offer a contrary perspective...those that made their decision based on his ideas..chose unwisely and seemingly did not do enough of their own due diligence.
After the bs the FDA pulled on Amarin at Adcom, who could blame Amarin for running the full trial anyway
My sentiments as well. If we were still sittin at 3 I doubt we would be hearing the fda cheerleading...sheesh.
How about all the dilution for starters...
JL, although yo sounds a bit harsh regarding the pps action resulting from favorable red-it trial results, I can't blame him for being somewhat jaded...I'm thinking half of the investment community feels the same way including myself. Never have I seen a company with good news after good news continue to decline in pps....
That's right, in NOLA we don't change our diet for nobody....now gimme sum of dem beignets please! Lol
Bólido...exactly! Those I know on statins in general have not changed ther diet at all...
Could...maybe this can shed light..
Recall in two Phase 3 trials, Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers. CANTOS and other recently reported studies help to increase our confidence in a positive and commercial outcome for REDUCE-IT. Also, CANTOS, together with other recent CV outcome studies […] have all served to lower the bar with respect to efficacy results, with less than 15% RRR viewed positively even for drugs with significant risks. AMRN has not lowered expectations for REDUCE-IT results, but this lowering of expectations from other studies, we feel, gives a comfortable starting point,” concludes the analyst, who underscores, “According to physicians, an 8%-10% risk reduction in CV events would be considered a success for REDUCE-IT. 15% would be great, and 20% would be exceptional results.”
Main...obviously there is no guarantee but here's some credible evidence regarding RRR. posted in aug 17
This past Sunday, at the European Society of Cardiology (ESC) Congress, Novartis posted a data read-out from its pivotal Phase 3 CANTOS trial assessing quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis. The results? Participants experienced a reduction in inflammation under the median hsCRP, an indicated 27% relative risk on primary MACE end-point.
This begs the following question: How exactly does Amarin Corporation plc (ADR) (NASDAQ:AMRN) fall into the cardiovascular therapy mix of Novartis’ results?
According to Cantor analyst Louise Chen, a great deal, as she trumpets, pay attention to “this catch of the day,” for the outcome proves her bullish contention: a long-term drug treatment with an anti-inflammatory mechanism in patients who have once had a heart attack and inflammatory atherosclerosis can offer a reduction of cardiovascular (CV) events. In other words, Novartis has just bolstered Chen’s conviction in Amarin’s REDUCE-IT (Reduction of Cardiovascular Events Outcomes) to clear the gates to an eventual solid commercial trajectory.
Fly anyone with common sense knows the market was due for a correction...the fact that Amarin had a shelf registration on the books which needed to be exercised within two years makes for excellent timing on their part (considering it happened Before the correction. Yes it broke the uptrend....for now.
Fly...are you implying Amarin wouldn't have tanked with the market had it not been for the capital raise? Lol.
Small company, small pockets....I'm guessing this is norm for a GIA situation...unless bp steps in and makes an offer to acquire or partner...what else can Amarin mgmt do?
Yo, consider the tiering of GL versus Vascepa...it's pretty shitty on part of the insurance carriers. So that being said, I thinks its admiral of the acceptance and growth of a small biotech.
So basically they only "flashed" a signal that as investors we should all be wary of...and that is the risk of failure. That's pretty much the risk in biotech anyways....and then of course the wild card...FDA
Tas, what do they need the money for if not for what is described...bonuses for themselves before or after failure? What is there annual cash burn, trial will be ending but there will still be expenses to that endeavor..
Hey don't think for a minute that I haven't realized what a ambush and con job FDA pulled on Amarin back in 2013. My point is that it would appear they couldn't give a flip what the diet supplement market claims are, but the distinction is hey if you want our label then ya gotta jump thru hoops and then maybe we might not screw ya over. So the DS market goes on its merry way making bs claims hoping the general public isn't savvy enough to make the distinction and more focused on saving a buck...
didn't FDA suggest Amarin go the DS route since they didn't get the labeling they wanted (around adcom timeframe)? Based On failed studies I.e. No reduction in cve events FDA not giving their seal of approval but could give a crap as to ds market?? When you look at omegavia website it has pharmaceutical grade wording...kinda misleading....
Current sales based on 200-500 trigs?..hmmm that would be off label, so could you provide the breakdown of sales for the 200-500 class, versus sales for the over 500 class (on label)?
I agree what we are seeing is manipulation....never have I seen a company put out such positive news so many times and the needle only moves a few degrees north. My bet is the option sellers are in charge....
Been holding and accumulating since 2010. Now that we have reached the home stretch I'm trying to be logical about the market value post reduce it. I just can't wait another 7 years for this company to build up a pie in the sky pps gia, so hoping for a buyout...but what will bp pony up? I think the shares outstanding has doubled since 2010. One thing I've learned about biotech...lots of rah rah, and then a big fart fizzle lol!
So you and slim believe the value post reduce it is $ per share times 336m outstanding and by is gonna step in and pony up? Just trying to gauge reality here!
Wonder how many shares outstanding at time of rumored offer of $20?
Assets: Cash, marketable securities, prepaid expenses, accounts receivable, inventory, and fixed assetS
Nice find...Amarin should somehow use this to educate and market to the general public!
Amen to that! Hard to get excited anymore after all the beatings starting with adcom. So much realization how corrupt the FDA can be...